Outro’s $7M bet on safer antidepressant tapering
Outro has raised $7 million in pre-seed and seed funding to build a clinical platform centered on safe deprescribing, starting with antidepressants. The New York-based company is positioning itself around a problem that often receives little structured attention in routine care: how to stop psychiatric medication without triggering avoidable withdrawal symptoms or a return of illness. Patients using the platform visit with clinicians trained in deprescribing, receive individualized tapering plans, and gain access to compounded medication doses designed to support dose reductions.
The financing round included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group and Pave Health Ventures. In a crowded digital mental health market, the capital is notable for what it is trying to fix rather than what it is trying to sell. Antidepressant prescribing has become commonplace in the United States, yet the practical infrastructure for stopping these drugs has lagged far behind initiation. A system built to start treatment now has to learn how to end it safely.
The company’s pitch is simple and clinically loaded at the same time. Thousands of patients remain on antidepressants long after the original indication has shifted, improved, or disappeared, but many cannot taper successfully because withdrawal symptoms emerge before the dose can be lowered enough. When the nervous system has adapted to chronic serotonergic exposure, abrupt or oversized reductions can provoke insomnia, dizziness, agitation, mood destabilization and other symptoms that patients often interpret as a relapse. In real practice, that uncertainty can trap people on a medication indefinitely, not because the drug is still clearly needed, but because there is no reliable off-ramp.
Hyperbolic tapering as the clinical engine
Outro’s platform is built around hyperbolic tapering, a dose-reduction method developed by company co-founder Dr. Mark Horowitz. Instead of lowering medication in equal steps, the approach uses progressively smaller decrements as the dose gets lower. Pharmacologically, the method makes sense because receptor occupancy and clinical effect do not fall in a straight line as doses decline; at low doses, even small reductions can represent a disproportionately large change in biologic exposure. For patients, that means the last stretch of a taper may be the most difficult part, not the beginning.
Horowitz’s research is central to the company’s argument. He has found that four in five long-term antidepressant users were unable to stop their medications because of withdrawal symptoms. The result is a forceful reminder that chronic antidepressant treatment is not just a matter of prescribing and continuing. It is also a matter of planning for discontinuation, and most care pathways still leave that phase underdeveloped.
“We want getting off a medication to be as supported as getting on it,” Brandon Goode, co-founder and CEO of Outro, said. The comment lands in a part of psychiatry that has often been treated as an afterthought. Clinicians are typically trained to initiate treatment, adjust dose, and monitor response. Far fewer have a structured framework for withdrawal management, patient counseling, and individualized dose-step design when symptoms surface during tapering.
A gap in psychiatric follow-through
Deprescribing guidance exists in other health systems, including the U.K., where tapering support has been available for years. In the United States, access is far more uneven, and patients frequently have to improvise reductions on their own or rely on short, inconsistent follow-up. For antidepressants, that gap has major consequences. A patient who has improved on medication may still fear stopping because one failed attempt can bring back distressing symptoms and convince both patient and clinician that continued use is the safer path.
That dynamic matters beyond one drug class. Outro plans to expand beyond antidepressants into other medications that also require deliberate discontinuation strategies, including benzodiazepines, gabapentinoids and GLP-1s. Each class carries its own physiologic and clinical challenges, but the common thread is the same: the body often adapts to ongoing exposure, and removing the drug too quickly can create harm that looks, at first glance, like the return of the original problem. For benzodiazepines, the risks can include rebound anxiety and more severe withdrawal phenomena. For GLP-1s, the issue may look different, but patients still need informed guidance when therapy ends.
Building infrastructure around stopping care
With the new funding, Outro plans to expand its network of deprescribing-trained clinicians and develop AI clinical decision support for deprescribing. The AI component is likely to be most useful if it can translate a difficult clinical art into a repeatable workflow: identifying medication class, duration of use, prior withdrawal history, symptom burden, dose form constraints and the pace at which a taper can safely proceed. If done well, decision support could help clinicians avoid the binary choice between abrupt cessation and indefinite continuation.
Listen Ventures framed the opportunity as a systems problem. “Outro is building the infrastructure, therapeutic options, and support for deprescribing, starting with antidepressants — a model we believe will become a standard part of modern healthcare,” Ellen Wilcox, partner at Listen Ventures, said in a statement. The statement reflects a broader shift in care delivery: medication management is increasingly being judged not only by how well treatment starts, but by whether it can be ended responsibly when circumstances change.
The clinical stakes are not abstract. Patients who feel abandoned during tapering may experience preventable distress, abandon attempts to stop treatment, or lose trust in future care plans. Clinicians who do not have dosage tools or structured protocols may default to the path of least resistance, even when the patient would prefer discontinuation. Outro is trying to change that transaction by combining trained clinicians, tapering methodology and medication access into one service.
The company’s next test is operational as much as scientific. It will need to show that deprescribing can be delivered reliably, at scale, and across drug classes with different withdrawal profiles. It will also need to prove that AI support improves care without flattening the individualized judgments that tapering often requires. For now, the funding gives Outro room to build a service around an area of medicine that has long been treated as peripheral, even though it sits squarely inside everyday prescribing.